Mucositis

Emma Bateman; Richard Logan; Rachel Gibson; Dorothy Keefe

doi:10.1007/978-3-319-77740-5_17

Mucositis

Emma Bateman, Richard Logan, Rachel Gibson, Dorothy Keefe

Research output: A Conference proceeding or a Chapter in Book › Chapter › peer-review

1 Citation (Scopus)

Abstract

Mucositis is an inflammatory reaction of the mucosa of the alimentary tract (AT) caused by chemotherapy, radiotherapy, and targeted therapy for cancer. It presents a significant burden not only to patient quality of life but also may result in diminished tumor control (through dose reductions) and increased treatment costs (due to extended hospital stays and supportive care). Mucositis symptoms may vary not only due to the treatment modality but also according to genetic predispositions of the patient toward developing toxicity (toxicogenomics). Management of mucositis is at present supportive only, with treatments that reduce incidence, severity, and duration of clinical symptoms, but do not prevent or cure mucositis altogether. A great deal of current research into the mechanisms involved in development and progression of mucositis is also being carried out; it is hoped that a clear understanding of mucositis pathophysiology, along with comprehensive toxicogenomics, will enable more preventative treatments to be developed.

Original language	English
Title of host publication	Textbook of Palliative Care
Publisher	Springer
Pages	317-333
Number of pages	17
ISBN (Electronic)	9783319777405
ISBN (Print)	9783319777382
DOIs	https://doi.org/10.1007/978-3-319-77740-5_17
Publication status	Published - 1 Jan 2019
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-3-319-77740-5_17

Cite this

@inbook{e8eecca944424cc6b38881b8159bc690,

title = "Mucositis",

abstract = "Mucositis is an inflammatory reaction of the mucosa of the alimentary tract (AT) caused by chemotherapy, radiotherapy, and targeted therapy for cancer. It presents a significant burden not only to patient quality of life but also may result in diminished tumor control (through dose reductions) and increased treatment costs (due to extended hospital stays and supportive care). Mucositis symptoms may vary not only due to the treatment modality but also according to genetic predispositions of the patient toward developing toxicity (toxicogenomics). Management of mucositis is at present supportive only, with treatments that reduce incidence, severity, and duration of clinical symptoms, but do not prevent or cure mucositis altogether. A great deal of current research into the mechanisms involved in development and progression of mucositis is also being carried out; it is hoped that a clear understanding of mucositis pathophysiology, along with comprehensive toxicogenomics, will enable more preventative treatments to be developed.",

author = "Emma Bateman and Richard Logan and Rachel Gibson and Dorothy Keefe",

note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2019",

year = "2019",

month = jan,

day = "1",

doi = "10.1007/978-3-319-77740-5_17",

language = "English",

isbn = "9783319777382",

pages = "317--333",

booktitle = "Textbook of Palliative Care",

publisher = "Springer",

address = "Netherlands",

}

TY - CHAP

T1 - Mucositis

AU - Bateman, Emma

AU - Logan, Richard

AU - Gibson, Rachel

AU - Keefe, Dorothy

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Mucositis is an inflammatory reaction of the mucosa of the alimentary tract (AT) caused by chemotherapy, radiotherapy, and targeted therapy for cancer. It presents a significant burden not only to patient quality of life but also may result in diminished tumor control (through dose reductions) and increased treatment costs (due to extended hospital stays and supportive care). Mucositis symptoms may vary not only due to the treatment modality but also according to genetic predispositions of the patient toward developing toxicity (toxicogenomics). Management of mucositis is at present supportive only, with treatments that reduce incidence, severity, and duration of clinical symptoms, but do not prevent or cure mucositis altogether. A great deal of current research into the mechanisms involved in development and progression of mucositis is also being carried out; it is hoped that a clear understanding of mucositis pathophysiology, along with comprehensive toxicogenomics, will enable more preventative treatments to be developed.

AB - Mucositis is an inflammatory reaction of the mucosa of the alimentary tract (AT) caused by chemotherapy, radiotherapy, and targeted therapy for cancer. It presents a significant burden not only to patient quality of life but also may result in diminished tumor control (through dose reductions) and increased treatment costs (due to extended hospital stays and supportive care). Mucositis symptoms may vary not only due to the treatment modality but also according to genetic predispositions of the patient toward developing toxicity (toxicogenomics). Management of mucositis is at present supportive only, with treatments that reduce incidence, severity, and duration of clinical symptoms, but do not prevent or cure mucositis altogether. A great deal of current research into the mechanisms involved in development and progression of mucositis is also being carried out; it is hoped that a clear understanding of mucositis pathophysiology, along with comprehensive toxicogenomics, will enable more preventative treatments to be developed.

UR - http://www.scopus.com/inward/record.url?scp=105013311395&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-77740-5_17

DO - 10.1007/978-3-319-77740-5_17

M3 - Chapter

AN - SCOPUS:105013311395

SN - 9783319777382

SP - 317

EP - 333

BT - Textbook of Palliative Care

PB - Springer

ER -

Mucositis

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this